Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATRA NASDAQ:ORIC NASDAQ:ORMP NASDAQ:PRQR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATRAAtara Biotherapeutics$8.44-15.0%$5.25$3.92▼$19.15$71.82M-0.31.23 million shs2.28 million shsORICOric Pharmaceuticals$8.89+1.0%$11.09$4.53▼$14.93$919.67M1.111.83 million shs532,722 shsORMPOramed Pharmaceuticals$4.05+3.6%$3.60$1.98▼$4.22$164.58M1.27180,022 shs86,817 shsPRQRProQR Therapeutics$1.61+1.6%$1.69$1.33▼$3.10$169.10M0.08524,695 shs547,530 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATRAAtara Biotherapeutics+92.82%+108.18%+110.83%+103.48%+36.78%ORICOric Pharmaceuticals-5.27%-10.83%-0.68%-15.45%+87.45%ORMPOramed Pharmaceuticals-0.26%+0.77%+11.08%+14.66%+76.13%PRQRProQR Therapeutics-8.14%+0.64%-7.06%+5.33%+0.64%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATRAAtara Biotherapeutics$8.44-15.0%$5.25$3.92▼$19.15$71.82M-0.31.23 million shs2.28 million shsORICOric Pharmaceuticals$8.89+1.0%$11.09$4.53▼$14.93$919.67M1.111.83 million shs532,722 shsORMPOramed Pharmaceuticals$4.05+3.6%$3.60$1.98▼$4.22$164.58M1.27180,022 shs86,817 shsPRQRProQR Therapeutics$1.61+1.6%$1.69$1.33▼$3.10$169.10M0.08524,695 shs547,530 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATRAAtara Biotherapeutics+92.82%+108.18%+110.83%+103.48%+36.78%ORICOric Pharmaceuticals-5.27%-10.83%-0.68%-15.45%+87.45%ORMPOramed Pharmaceuticals-0.26%+0.77%+11.08%+14.66%+76.13%PRQRProQR Therapeutics-8.14%+0.64%-7.06%+5.33%+0.64%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATRAAtara Biotherapeutics 2.00Hold$9.5012.56% UpsideORICOric Pharmaceuticals 2.71Moderate Buy$19.80122.62% UpsideORMPOramed Pharmaceuticals 2.00HoldN/AN/APRQRProQR Therapeutics 2.63Moderate Buy$7.25351.71% UpsideCurrent Analyst Ratings BreakdownLatest ATRA, ORIC, PRQR, and ORMP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2026ATRAAtara Biotherapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetHold ➝ Buy$13.005/5/2026ORICOric Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$17.00 ➝ $16.004/21/2026ORICOric Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026PRQRProQR Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/9/2026PRQRProQR Therapeutics Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$4.004/2/2026ORICOric Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.004/1/2026ORICOric Pharmaceuticals WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$20.00 ➝ $17.003/27/2026ATRAAtara Biotherapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)3/27/2026ORMPOramed Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)3/13/2026PRQRProQR Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform3/13/2026ORICOric Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.00(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATRAAtara Biotherapeutics$120.77M0.59$7.96 per share1.06($5.34) per share-1.58ORICOric PharmaceuticalsN/AN/AN/AN/A$4.01 per shareN/AORMPOramed Pharmaceuticals$2M81.92$0.09 per share43.21$5.02 per share0.81PRQRProQR Therapeutics$17.99M9.40N/AN/A$0.53 per share3.03Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATRAAtara Biotherapeutics$32.69M$3.122.7142.20N/A27.07%-79.12%87.55%5/21/2026 (Estimated)ORICOric Pharmaceuticals-$129.47M-$1.44N/AN/AN/AN/A-35.33%-33.31%N/AORMPOramed Pharmaceuticals$64.05M$1.492.73N/AN/AN/A-6.83%-6.25%N/APRQRProQR Therapeutics-$47.73M-$0.46N/AN/AN/A-255.83%-65.89%-31.53%5/14/2026 (Estimated)Latest ATRA, ORIC, PRQR, and ORMP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2026Q1 2026ATRAAtara Biotherapeutics-$0.3295N/AN/AN/A$2.90 millionN/A5/14/2026Q1 2026PRQRProQR Therapeutics-$0.15N/AN/AN/A$5.19 millionN/A5/4/2026Q1 2026ORICOric Pharmaceuticals-$0.31-$0.34-$0.03-$0.34N/AN/A3/27/2026Q4 2025ORMPOramed Pharmaceuticals-$0.08-$0.06+$0.02$0.24$0.50 millionN/A3/16/2026Q4 2025ATRAAtara Biotherapeutics-$0.68-$0.25+$0.43-$0.36$0.70 million$1.60 million3/12/2026Q4 2025PRQRProQR Therapeutics-$0.08-$0.09-$0.01-$0.09$6.12 million$5.53 million2/23/2026Q4 2025ORICOric Pharmaceuticals-$0.34-$0.30+$0.04-$0.30N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthATRAAtara BiotherapeuticsN/AN/AN/AN/AN/AORICOric PharmaceuticalsN/AN/AN/AN/AN/AORMPOramed Pharmaceuticals$0.256.17%N/A16.78%N/APRQRProQR TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATRAAtara BiotherapeuticsN/A0.820.82ORICOric PharmaceuticalsN/A16.3314.13ORMPOramed PharmaceuticalsN/A6.986.98PRQRProQR TherapeuticsN/A3.093.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATRAAtara Biotherapeutics70.90%ORICOric Pharmaceuticals95.05%ORMPOramed Pharmaceuticals12.73%PRQRProQR Therapeutics32.65%Insider OwnershipCompanyInsider OwnershipATRAAtara Biotherapeutics41.20%ORICOric Pharmaceuticals6.82%ORMPOramed Pharmaceuticals17.80%PRQRProQR Therapeutics8.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATRAAtara Biotherapeutics3308.51 million5.01 millionNo DataORICOric Pharmaceuticals80103.52 million96.46 millionOptionableORMPOramed Pharmaceuticals1040.45 million33.25 millionOptionablePRQRProQR Therapeutics180105.36 million96.51 millionOptionableATRA, ORIC, PRQR, and ORMP HeadlinesRecent News About These CompaniesEarnings Preview: ProQR (PRQR) Q1 Earnings Expected to DeclineMay 7 at 11:01 AM | zacks.comProQR Therapeutics (PRQR) to Release Quarterly Earnings on ThursdayMay 7 at 4:05 AM | marketbeat.comProQR Announces Annual General Meeting of Shareholders to be Held June 2, 2026May 4, 2026 | globenewswire.comProQR Announces Nomination of Dr. Lykke Hinsch Gylvin to its Board of DirectorsApril 30, 2026 | globenewswire.comProQR Therapeutics N.V. (NASDAQ:PRQR) Short Interest Down 24.4% in AprilApril 29, 2026 | marketbeat.comProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Consensus Rating of "Moderate Buy" from AnalystsApril 26, 2026 | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Stock Price Passes Above 50 Day Moving Average - Should You Sell?April 25, 2026 | marketbeat.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Alkermes (ALKS), ProQR (PRQR) and Simulations Plus (SLP)April 10, 2026 | theglobeandmail.comProQR Therapeutics: Waiting On Proof As AX-0810 Data ApproachesApril 10, 2026 | seekingalpha.comProQR Therapeutics (NASDAQ:PRQR) Earns "Buy" Rating from Chardan CapitalApril 9, 2026 | marketbeat.comAberdeen Group plc Has $5.96 Million Holdings in ProQR Therapeutics N.V. $PRQRApril 9, 2026 | marketbeat.comProQR Highlights Pipeline Expansion and Multiple Upcoming Clinical Catalysts at Investor and Analyst EventApril 8, 2026 | globenewswire.comProQR Therapeutics Unveils New RNA Editing Programs; AX-0810 Phase 1 Target Data Due This QuarterApril 8, 2026 | marketbeat.comProQR Announces Partnership with Ginkgo Bioworks and Formation of AI Advisory BoardApril 8, 2026 | globenewswire.comGrowing optimism about ProQR Therapeutics (PRQR)’s RNA editing platform and future clinical catalystsMarch 26, 2026 | msn.comGrowing Optimism About ProQR Therapeutics (PRQR)’s RNA Editing Platform and Future Clinical CatalystsMarch 25, 2026 | insidermonkey.comProQR to Host Virtual Investor and Analyst Event Highlighting Pipeline on April 8, 2026March 25, 2026 | globenewswire.comProQR Therapeutics N.V. (PRQR) Presents at The Citizens Life Sciences Conference 2026 TranscriptMarch 18, 2026 | seekingalpha.comProQR (PRQR) Reports Q4 Loss, Lags Revenue EstimatesMarch 12, 2026 | zacks.comProQR Therapeutics N.V.: ProQR Announces Year End 2025 Operating and Financial ResultsMarch 12, 2026 | finanznachrichten.deProQR Announces Year End 2025 Operating and Financial ResultsMarch 12, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Nasdaq's Historic Rally Doesn't Mean the Risk Is GoneBy Bridget Bennett | April 19, 2026Apple Talks Just Changed Everything for IntelBy Sam Quirke | May 6, 2026Lumentum's 1,500% Run and Nvidia's $2 Billion Deal: What Comes Next?By Chris Markoch | April 9, 2026Churchill Downs: The Derby Is Just the BeginningBy Chris Markoch | April 24, 20263 Stocks Flashing Rare Buy Signals After the Market's Wildest MonthBy Bridget Bennett | April 21, 2026ATRA, ORIC, PRQR, and ORMP Company DescriptionsAtara Biotherapeutics NASDAQ:ATRA$8.44 -1.49 (-15.01%) As of 01:10 PM EasternAtara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.Oric Pharmaceuticals NASDAQ:ORIC$8.89 +0.08 (+0.95%) As of 01:25 PM Eastern This is a fair market value price provided by Massive. Learn more.ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.Oramed Pharmaceuticals NASDAQ:ORMP$4.05 +0.14 (+3.61%) As of 01:25 PM Eastern This is a fair market value price provided by Massive. Learn more.Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.ProQR Therapeutics NASDAQ:PRQR$1.60 +0.03 (+1.58%) As of 01:25 PM Eastern This is a fair market value price provided by Massive. Learn more.ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Wells Fargo’s Comeback Is Real—But Not Risk-Free Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
